Epidermal growth factor-containing wound closure enhances wound healing in non-diabetic and diabetic rats.
BACKGROUND
This study was designed to elucidate the in vivo efficacy of epidermal growth factor (EGF) on wound healing in non diabetic and diabetic rats.


METHODS
Ninety-six male Wistar-Albino rats were randomly divided into six groups. Saline-moistened gauze, pure gelatin or EGF in gelatin-microsphere dressings were used in a dermal excision model in both normal and streptomycin-induced diabetic rats. Wound healing was evaluated on day 7 and 14. Reduction in wound area, hydroxypyroline content and tensile strength of the wound were evaluated in each rat. Tissue samples taken from the wounds were examined histopathologically for reepithelialisation, cellular infiltration, number of fibroblasts, granulation and neovascularisation.


RESULTS
On day 7, the use of EGF-containing dressing was observed to reduce the wound area better when compared with the other dressings tested. This effect was significant in normal rats rather than diabetic rats. The difference in reduction of wound area did not persist on day 14. No significant effect on hydroxyproline content of the wound was found with EGF-containing dressing in either normal or diabetic rats. There was a statistically significant increase in tensile strength values of EGF-applied non diabetic rats over the 14 day period. An increase in tensile strength was prominent in also EGF-applied diabetic rats on day 14. Histological examination revealed higher histopathologic scores in EGF-applied diabetic and non diabetic rats.


CONCLUSIONS
These findings implicate that use of EGF in gelatin-microsphere dressings improves wound healing both in normal and diabetic rats.
Dogan
S
S
Ankara University School of Medicine, Department of General Surgery, Ankara, Turkey.
Demirer
S
S
Kepenekci
I
I
Erkek
B
B
Kiziltay
A
A
Hasirci
N
N
Müftüoglu
S
S
Nazikoglu
A
A
Renda
N
N
Dincer
U D
UD
Elhan
A
A
Kuterdem
E
E
D000287:Administration, Topical; D000818:Animals; D003921:Diabetes Mellitus, Experimental; D004815:Epidermal Growth Factor / Q000008:administration & dosage*; D005781:Gelatin Sponge, Absorbable / Q000008:administration & dosage* / Q000737:chemistry; D008297:Male; D008863:Microspheres; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology; D014950:Wounds, Penetrating / Q000188:drug therapy
D013311:Streptozocin; D004815:Epidermal Growth Factor